Abstract
Background: Thromboembolic events (TEEs) may significantly complicate the clinical management of patients with testicular germ cell tumours (GCTs). We analysed a cohort of GCT patients for the occurrence of TEEs and looked to possible pathogenetic factors. Patients, Methods: TEEs occurring within 6 months after diagnosis were retrospectively analysed in 317 consecutive patients with testicular GCT (median age 37 years, 198 seminoma, 119 nonseminoma). The following factors were analysed for association with TEE: histology, age, clinical stage (CS), chemotherapy, use of a central venous access device (CVA). Data analysis involved descriptive statistical methods with multivariable analysis to identify independent risk factors. Results: Twenty-three TEEs (7.3%) were observed, 18 deep vein thromboses, 4 pulmonary embolisms, and 1 myocardial infarction. Univariable risk calculation yielded the following odds ratios (ORs) : >CS1 OR = 43.7 (95% confidence intervals [CIs] 9.9–191.6); chemotherapy OR = 7.8 (95% CI 2.3–26.6); CVA OR = 30.5 (95% CI 11.0–84.3). Multivariable analysis identified only CS > 1 (OR = 16.9; 95% CI 3.5–82.4) and CVA (OR = 9.0; 95% CI 2.9–27.5) as independent risk factors. Conclusions: Patients with CSs >CS1 are at significantly increased risk of TEEs even without chemotherapy. Particular high risk is associated with the use of CVA devices for chemotherapy. Caregivers of GCT patients must be aware of the particular risk of TEEs.
Journal Section:
Editor's choice
References
1.
Boyer
M
, Raghavan
D
. Toxicity of treatment of germ cell tumors
. Semin Oncol
. 1992
;19
(2
):128
–42
.2.
Falanga
A
, Russo
L
, Milesi
V
, Vignoli
A
. Mechanisms and risk factors of thrombosis in cancer
. Crit Rev Oncol Hematol
. 2017
;118
:79
–83
.3.
Nichols
CR
, Roth
BJ
, Williams
SD
, Gill
I
, Muggia
FM
, Stablein
DM
, . No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: an analysis of the testicular cancer intergroup study
. J Clin Oncol
. 1992
;10
(5
):760
–5
.4.
Lederman
GS
, Garnick
MB
. Pulmonary emboli as a complication of germ cell cancer treatment
. J Urol
. 1987
;137
(6
):1236
–7
.5.
Cantwell
BM
, Mannix
KA
, Roberts
JT
, Ghani
SE
, Harris
AL
. Thromboembolic events during combination chemotherapy for germ cell-malignancy
. Lancet
. 1988
;2
(8619
):1086
–7
.6.
Weijl
NI
, Rutten
MF
, Zwinderman
AH
, Keizer
HJ
, Nooy
MA
, Rosendaal
FR
, . Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature
. J Clin Oncol
. 2000
;18
(10
):2169
–78
.7.
Piketty
AC
, Fléchon
A
, Laplanche
A
, Nouyrigat
E
, Droz
JP
, Théodore
C
, . The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area
. Br J Cancer
. 2005
;93
(8
):909
–14
.8.
Gonzalez-Billalabeitia
E
, Castellano
D
, Sobrevilla
N
, Guma
J
, Hervas
D
, Luengo
MI
, . Prognostic significance of venous thromboembolic events in disseminated germ cell cancer patients
. J Natl Cancer Inst
. 2017
;109
;djw265
.9.
Dieckmann
KP
, Anheuser
P
, Gehrckens
R
, Aries
SP
, Ikogho
R
, Hollburg
W
. Factor V Leiden mutation triggering four major complications to standard dose cisplatin-chemotherapy for testicular seminoma: a case report
. BMC Urol
. 2015
;15
:21
.10.
Nestler
T
, Huber
J
, Laury
AM
, Isbarn
H
, Heidenreich
A
, Schmelz
HU
, . Thromboprophylaxis and the route of administration of chemotherapy in testicular cancer patients in German-speaking countries
. World J Urol
. 2018
;36
(6
):913
–20
.11.
de Haas
EC
, Zwart
N
, Meijer
C
, Suurmeijer
AJ
, Meijer
K
, Guchelaar
HJ
, . Association of PAI-1 gene polymorphism with survival and chemotherapy-related vascular toxicity in testicular cancer
. Cancer
. 2010
;116
(24
):5628
–36
.12.
Lubberts
S
, Boer
H
, Altena
R
, Meijer
C
, van Roon
AM
, Zwart
N
, . Vascular fingerprint and vascular damage markers associated with vascular events in testicular cancer patients during and after chemotherapy
. Eur J Cancer
. 2016
;63
:180
–8
.13.
Gizzi
M
, Oberic
L
, Massard
C
, Poterie
A
, Gwenael
LT
, Loriot
Y
, . Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours
. Eur J Cancer
. 2016
;69
:151
–7
.14.
Heidegger
I
, Porres
D
, Veek
N
, Heidenreich
A
, Pfister
D
. Predictive factors for developing venous thrombosis during cisplatin-based chemotherapy in testicular cancer
. Urol Int
. 2017
;99
(1
):104
–9
.15.
Honecker
F
, Koychev
D
, Luhmann
AD
, Langer
F
, Dieckmann
KP
, Bokemeyer
C
, . Venous thromboembolic events in germ cell cancer patients undergoing platinum-based chemotherapy
. Onkologie
. 2013
;36
(11
):663
–8
.16.
Paffenholz
P
, Grein
K
, Heidegger
I
, Nestler
T
, Grabbert
M
, Salem
J
, . Predictors of thrombosis in testicular cancer during platinum-based chemotherapy
. World J Urol
. 2019
;37
(9
):1907
–16
.17.
Solari
L
, Krönig
M
, Ihorst
G
, Drognitz
K
, Heinz
J
, Jilg
CA
, . High rates of thromboembolic events in patients with germ cell cancer undergoing cisplatin-based polychemotherapy
. Urol Int
. 2016
;96
(4
):399
–405
.18.
Srikanthan
A
, Tran
B
, Beausoleil
M
, Jewett
MA
, Hamilton
RJ
, Sturgeon
JF
, . Large retroperitoneal lymphadenopathy as a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy
. J Clin Oncol
. 2015
;33
(6
):582
–7
.19.
Tran
B
, Ruiz-Morales
JM
, Gonzalez-Billalabeitia
E
, Patrikidou
A
, Amir
E
, Seidel
C
, . Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: a study by the global germ cell cancer group (G3)
. Cancer Med
. 2020
;9
(1
):116
–24
.20.
Worst
T
, Sautter
L
, John
A
, Weiss
C
, Häcker
A
, Heinzelbecker
J
. Cisplatin-based chemotherapy for testicular germ cell tumors: complication rates of peripheral versus central venous administration
. Urol Int
. 2016
;96
(2
):177
–82
.21.
Nitta
S
, Kawai
K
, Kimura
T
, Kawahara
T
, Kandori
S
, Hoshi
A
, . Predictors of venous thromboembolism development before and during chemotherapy for advanced germ cell tumor
. Jpn J Clin Oncol
. 2020
;50
(3
):338
–43
.22.
Thorsen
L
, Haugnes
HS
, Fosså
SD
, Brydøy
M
, Tandstad
T
, Wisløff
T
, . Thromboembolic events after high‐intensity training during cisplatin‐based chemotherapy for testicular cancer: case reports and review of the literature
. Int J Cancer
. 2020
:147
(11
);3189
–98
.23.
Brinkmann
M
, Tallone
EM
, Würschmidt
F
, Wülfing
C
, Dieckmann
KP
. [Myocardial infarction in a young patient with seminoma during chemotherapy with cisplatinum, etoposide, and bleomycin].[Article in German]
. Aktuelle Urol
. 2018
.http://dx.doi.org/10.1055/a-0649-4878.24.
Bezan
A
, Posch
F
, Ploner
F
, Bauernhofer
T
, Pichler
M
, Szkandera
J
, . Risk stratification for venous thromboembolism in patients with testicular germ cell tumors
. PLoS One
. 2017
;12
(4
):e0176283
.25.
Khorana
AA
, Kuderer
NM
, Culakova
E
, Lyman
GH
, Francis
CW
. Development and validation of a predictive model for chemotherapy-associated thrombosis
. Blood
. 2008
;111
(10
):4902
–7
.26.
Moore
RA
, Adel
N
, Riedel
E
, Bhutani
M
, Feldman
DR
, Tabbara
NE
, . High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis
. J Clin Oncol
. 2011
;29
(25
):3466
–73
.27.
Dieckmann
KP
, Gerl
A
, Witt
J
, Hartmann
JT
, German Testicular Cancer Study Group
.. Myocardial infarction and other major vascular events during chemotherapy for testicular cancer
. Ann Oncol
. 2010
;21
(8
):1607
–11
.28.
Nuver
J
, Smit
AJ
, van der Meer
J
, van den Berg
MP
, van der Graaf
WT
, Meinardi
MT
, . Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer
. J Clin Oncol
. 2005
;23
(36
):9130
–7
.29.
Lemmers
NW
, Gels
ME
, Sleijfer
DT
, Plukker
JT
, van der Graaf
WT
, de Langen
ZJ
, . Complications of venous access ports in 132 patients with disseminated testicular cancer treated with polychemotherapy
. J Clin Oncol
. 1996
;14
(11
):2916
–22
.30.
Baumann Kreuziger
L
, Jaffray
J
, Carrier
M
. Epidemiology, diagnosis, prevention and treatment of catheter-related thrombosis in children and adults
. Thromb Res
. 2017
;157
:64
–71
.31.
Piran
S
, Ngo
V
, McDiarmid
S
, Le Gal
G
, Petrcich
W
, Carrier
M
. Incidence and risk factors of symptomatic venous thromboembolism related to implanted ports in cancer patients
. Thromb Res
. 2014
;133
(1
):30
–3
.32.
Key
NS
, Khorana
AA
, Kuderer
NM
, Bohlke
K
, Lee
AYY
, Arcelus
JI
, . Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update
. J Clin Oncol
. 2020
;38
(5
):496
–520
.33.
Rossel
A
, Robert-Ebadi
H
, Marti
C
. Preventing venous thromboembolism in ambulatory patients with cancer: a narrative review
. Cancers
. 2020
;12
:612
.© 2020 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2020
You do not currently have access to this content.
